Research ExplorerPublicationsIn Vivo Detection of Circulating Tumor Cells in High-Risk No...

In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy

Standard

In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy. / Chen, Shukun; Tauber, Gerlinde; Langsenlehner, Tanja; Schmölzer, Linda Maria; Pötscher, Michaela; Riethdorf, Sabine; Kuske, Andra; Leitinger, Gerd; Kashofer, Karl; Czyż, Zbigniew T; Polzer, Bernhard; Pantel, Klaus; Sedlmayr, Peter; Kroneis, Thomas; El-Heliebi, Amin.

In: CANCERS, Vol. 11, No. 7, 03.07.2019.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Chen, S, Tauber, G, Langsenlehner, T, Schmölzer, LM, Pötscher, M, Riethdorf, S, Kuske, A, Leitinger, G, Kashofer, K, Czyż, ZT, Polzer, B, Pantel, K, Sedlmayr, P, Kroneis, T & El-Heliebi, A 2019, 'In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy', CANCERS, vol. 11, no. 7. https://doi.org/10.3390/cancers11070933

APA

Chen, S., Tauber, G., Langsenlehner, T., Schmölzer, L. M., Pötscher, M., Riethdorf, S., Kuske, A., Leitinger, G., Kashofer, K., Czyż, Z. T., Polzer, B., Pantel, K., Sedlmayr, P., Kroneis, T., & El-Heliebi, A. (2019). In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy. CANCERS, 11(7). https://doi.org/10.3390/cancers11070933

Vancouver

Chen S, Tauber G, Langsenlehner T, Schmölzer LM, Pötscher M, Riethdorf S et al. In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy. CANCERS. 2019 Jul 3;11(7). https://doi.org/10.3390/cancers11070933

Bibtex

@article{792eff1fbc764fe9a972a15b68d87c3b,
title = "In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy",
abstract = "High-risk non-metastatic prostate cancer (PCa) has the potential to progress into lethal disease. Treatment options are manifold but, given a lack of surrogate biomarkers, it remains unclear which treatment offers the best results. Several studies have reported circulating tumor cells (CTCs) to be a prognostic biomarker in metastatic PCa. However, few reports on CTCs in high-risk non-metastatic PCa are available. Herein, we evaluated CTC detection in high-risk non-metastatic PCa patients using the in vivo CellCollector CANCER01 (DC01) and CellSearch system. CTC counts were analyzed and compared before and after radiotherapy (two sampling time points) in 51 high-risk non-metastatic PCa patients and were further compared according to isolation technique; further, CTC counts were correlated to clinical features. Use of DC01 resulted in a significantly higher percentage of CTC-positive samples compared to CellSearch (33.7% vs. 18.6%; p = 0.024) and yielded significantly higher CTC numbers (range: 0-15 vs. 0-5; p = 0.006). Matched pair analysis of samples between two sampling time points showed no difference in CTC counts determined by both techniques. CTC counts were not correlated with clinicopathological features. In vivo enrichment using DC01 has the potential to detect CTC at a higher efficiency compared to CellSearch, suggesting that CTC is a suitable biomarker in high-risk non-metastatic PCa.",
author = "Shukun Chen and Gerlinde Tauber and Tanja Langsenlehner and Schm{\"o}lzer, {Linda Maria} and Michaela P{\"o}tscher and Sabine Riethdorf and Andra Kuske and Gerd Leitinger and Karl Kashofer and Czy{\.z}, {Zbigniew T} and Bernhard Polzer and Klaus Pantel and Peter Sedlmayr and Thomas Kroneis and Amin El-Heliebi",
year = "2019",
month = jul,
day = "3",
doi = "10.3390/cancers11070933",
language = "English",
volume = "11",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

RIS

TY - JOUR

T1 - In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy

AU - Chen, Shukun

AU - Tauber, Gerlinde

AU - Langsenlehner, Tanja

AU - Schmölzer, Linda Maria

AU - Pötscher, Michaela

AU - Riethdorf, Sabine

AU - Kuske, Andra

AU - Leitinger, Gerd

AU - Kashofer, Karl

AU - Czyż, Zbigniew T

AU - Polzer, Bernhard

AU - Pantel, Klaus

AU - Sedlmayr, Peter

AU - Kroneis, Thomas

AU - El-Heliebi, Amin

PY - 2019/7/3

Y1 - 2019/7/3

N2 - High-risk non-metastatic prostate cancer (PCa) has the potential to progress into lethal disease. Treatment options are manifold but, given a lack of surrogate biomarkers, it remains unclear which treatment offers the best results. Several studies have reported circulating tumor cells (CTCs) to be a prognostic biomarker in metastatic PCa. However, few reports on CTCs in high-risk non-metastatic PCa are available. Herein, we evaluated CTC detection in high-risk non-metastatic PCa patients using the in vivo CellCollector CANCER01 (DC01) and CellSearch system. CTC counts were analyzed and compared before and after radiotherapy (two sampling time points) in 51 high-risk non-metastatic PCa patients and were further compared according to isolation technique; further, CTC counts were correlated to clinical features. Use of DC01 resulted in a significantly higher percentage of CTC-positive samples compared to CellSearch (33.7% vs. 18.6%; p = 0.024) and yielded significantly higher CTC numbers (range: 0-15 vs. 0-5; p = 0.006). Matched pair analysis of samples between two sampling time points showed no difference in CTC counts determined by both techniques. CTC counts were not correlated with clinicopathological features. In vivo enrichment using DC01 has the potential to detect CTC at a higher efficiency compared to CellSearch, suggesting that CTC is a suitable biomarker in high-risk non-metastatic PCa.

AB - High-risk non-metastatic prostate cancer (PCa) has the potential to progress into lethal disease. Treatment options are manifold but, given a lack of surrogate biomarkers, it remains unclear which treatment offers the best results. Several studies have reported circulating tumor cells (CTCs) to be a prognostic biomarker in metastatic PCa. However, few reports on CTCs in high-risk non-metastatic PCa are available. Herein, we evaluated CTC detection in high-risk non-metastatic PCa patients using the in vivo CellCollector CANCER01 (DC01) and CellSearch system. CTC counts were analyzed and compared before and after radiotherapy (two sampling time points) in 51 high-risk non-metastatic PCa patients and were further compared according to isolation technique; further, CTC counts were correlated to clinical features. Use of DC01 resulted in a significantly higher percentage of CTC-positive samples compared to CellSearch (33.7% vs. 18.6%; p = 0.024) and yielded significantly higher CTC numbers (range: 0-15 vs. 0-5; p = 0.006). Matched pair analysis of samples between two sampling time points showed no difference in CTC counts determined by both techniques. CTC counts were not correlated with clinicopathological features. In vivo enrichment using DC01 has the potential to detect CTC at a higher efficiency compared to CellSearch, suggesting that CTC is a suitable biomarker in high-risk non-metastatic PCa.

U2 - 10.3390/cancers11070933

DO - 10.3390/cancers11070933

M3 - SCORING: Journal article

C2 - 31277254

VL - 11

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 7

ER -